Purav Patel - 18 Dec 2025 Form 4 Insider Report for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)

Role: Director
Signature: /s/ Narayan Prabhu, attorney-in-fact for Purav Patel
Issuer symbol: RVPH
Transactions as of: 18 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 19 Dec 2025, 16:17:45 UTC
Previous filing: 12 Dec 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Patel Purav	Director	C/O REVIVA PHARMACEUTICALS HOLDINGS, INC, 10080 N WOLFE ROAD, SUITE SW3-200, CUPERTINO	/s/ Narayan Prabhu, attorney-in-fact for Purav Patel	19 Dec 2025	0001818246

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVPH	Stock Option (right to buy)	Award	$0	+8,200		$0.000000	8,200	18 Dec 2025	Common Stock, par value $0.0001 per share	8,200	$0.5848	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

Content

This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.